Clinical Study Comparing Two Implant Surface Finishes in Patients Undergoing Cementless Total Hip Replacement

This study has been terminated.
(Terminated due to limited enrollment and follow up.)
Sponsor:
Information provided by (Responsible Party):
DePuy Orthopaedics
ClinicalTrials.gov Identifier:
NCT00306917
First received: March 23, 2006
Last updated: December 1, 2011
Last verified: December 2011
Results First Received: January 29, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Osteoarthritis
Rheumatoid Arthritis
Post-traumatic Arthritis
Avascular Necrosis
Acute Fracture
Interventions: Device: non-coated femoral hip stem
Device: coated femoral hip stem

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment began in September 2002 and ended June 2006. Study subjects were recruited and enrolled in medical clinics by orthopaedic surgeons at eight investigational sites. Each site could enroll a maximum of 50 subjects. Recruitment was based on the inclusion and exclusion criteria as indicated in the study protocol.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Immediately before surgery, the implant type was determined according to the randomization schedule. Enrolled subjects may have been excluded from the trial before assignment to the study arm based upon results of pre-operative clinical evaluations and radiographs that would exclude a subject based on exclusion criteria in the study protocol.

Reporting Groups
  Description
DuoFix HA The Summit™ DuoFix™ HA stems are primary, cementless hip implants. Summit™ cementless stems feature 3°-tapered body geometry to enhance fit, and are manufactured from forged titanium alloy. The Summit™ cementless stems are designed to load the femur toward the upper part of the stem, and therefore the Porocoat® porous coating is applied only to the upper body of the stem. The DuoFix™ HA stem also has a thin coating of hydroxyapatite on this porous-coated surface. This HA coating is only 35 microns thick, so the optimum pore size is maintained. The lower portion of the stem has a grit-blasted surface, which promotes bone on-growth and the polished bullet-tip prevents end-stem loading.
Porocoat Porous Coated The Summit™ Porocoat® stems are primary, cementless hip implants that a feature 3°-tapered body geometry to enhance fit, and are manufactured from forged titanium alloy. The Summit™ cementless stems are designed to load the femur toward the upper part of the stem, and therefore the Porocoat® porous coating is applied only to the upper body of the stem. The lower portion of the stems has a grit-blasted surface, which promotes bone on-growth and the polished bullet-tip prevents end-stem loading.

Participant Flow:   Overall Study
    DuoFix HA     Porocoat Porous Coated  
STARTED     121 [1]   124 [1]
Postoperative to 6 Month Follow up     93     100  
12 Month Follow     86     94  
24 Month Follow up     60     71  
36 Month Follow up     56     42  
48 Month Follow up     29     22  
60 Month Follow up     13     15  
COMPLETED     13     15  
NOT COMPLETED     108     109  
[1] 400 subjects were to be followed for 5 years; due to slow enrollment study closed early with 245.



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
DuoFix HA The Summit™ DuoFix™ HA stems are primary, cementless hip implants. Summit™ cementless stems feature 3°-tapered body geometry to enhance fit, and are manufactured from forged titanium alloy. The Summit™ cementless stems are designed to load the femur toward the upper part of the stem, and therefore the Porocoat® porous coating is applied only to the upper body of the stem. The DuoFix™ HA stem also has a thin coating of hydroxyapatite on this porous-coated surface. This HA coating is only 35 microns thick, so the optimum pore size is maintained. The lower portion of the stem has a grit-blasted surface, which promotes bone on-growth and the polished bullet-tip prevents end-stem loading.
Porocoat Porous Coated The Summit™ Porocoat® stems are primary, cementless hip implants that a feature 3°-tapered body geometry to enhance fit, and are manufactured from forged titanium alloy. The Summit™ cementless stems are designed to load the femur toward the upper part of the stem, and therefore the Porocoat® porous coating is applied only to the upper body of the stem. The lower portion of the stems has a grit-blasted surface, which promotes bone on-growth and the polished bullet-tip prevents end-stem loading.
Total Total of all reporting groups

Baseline Measures
    DuoFix HA     Porocoat Porous Coated     Total  
Number of Participants  
[units: participants]
  121     124     245  
Age  
[units: years]
Mean ± Standard Deviation
  64.5  ± 8.2     63.2  ± 9.2     63.8  ± 8.7  
Gender  
[units: participants]
     
Female     67     64     131  
Male     54     60     114  
Region of Enrollment  
[units: participants]
     
United States     121     124     245  



  Outcome Measures

1.  Primary:   Harris Hip Score (HHS)   [ Time Frame: Preoperative, 6, 12, 24, 36, 48, and 60 months ]

2.  Secondary:   Medical Imaging   [ Time Frame: postoperative, 6, 12, 24, 36, 48 and 60 months ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   Yes


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
DuoFix HA The Summit™ DuoFix™ HA stems are primary, cementless hip implants. Summit™ cementless stems feature 3°-tapered body geometry to enhance fit, and are manufactured from forged titanium alloy. The Summit™ cementless stems are designed to load the femur toward the upper part of the stem, and therefore the Porocoat® porous coating is applied only to the upper body of the stem. The DuoFix™ HA stem also has a thin coating of hydroxyapatite on this porous-coated surface. This HA coating is only 35 microns thick, so the optimum pore size is maintained. The lower portion of the stem has a grit-blasted surface, which promotes bone on-growth and the polished bullet-tip prevents end-stem loading.
Porocoat Porous Coated The Summit™ Porocoat® stems are primary, cementless hip implants that a feature 3°-tapered body geometry to enhance fit, and are manufactured from forged titanium alloy. The Summit™ cementless stems are designed to load the femur toward the upper part of the stem, and therefore the Porocoat® porous coating is applied only to the upper body of the stem. The lower portion of the stems has a grit-blasted surface, which promotes bone on-growth and the polished bullet-tip prevents end-stem loading.

Other Adverse Events
    DuoFix HA     Porocoat Porous Coated  
Total, other (not including serious) adverse events      
# participants affected / at risk     6/121     7/124  
Blood and lymphatic system disorders      
Blood Loss Anemia      
# participants affected / at risk     6/121 (4.96%)     7/124 (5.65%)  
# events     6     7  



  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The protocol called for 400 subjects to be followed for 5 years, but due to slow enrollment the study closed early. 245 subjects were enrolled & study endpoint was modified to 2 years. Enrollment closed on June 30, 2006; study closed on Jan 29, 2009.  


Results Point of Contact:  
Name/Title: Barry Sisson
Organization: DePuy Orthopaedics, Inc
phone: 574-372-7156
e-mail: BSisson@its.jnj.com


No publications provided


Responsible Party: DePuy Orthopaedics
ClinicalTrials.gov Identifier: NCT00306917     History of Changes
Other Study ID Numbers: SPD
Study First Received: March 23, 2006
Results First Received: January 29, 2010
Last Updated: December 1, 2011
Health Authority: United States: Food and Drug Administration